Journal of the European Academy of Dermatology and Venereology

<jats:title>Abstract</jats:title><jats:p>This manuscript provides expert recommendations on the role of allogeneic haematopoietic cell transplantation (allo‐HCT) for cutaneous T‐cell lymphoma (CTCL), specifically mycosis fungoides (MF) and Sezary syndrome (SS). Critical aspects such as patient selection, timing, and bridging therapy are addressed, as well as donor source, conditioning regimens and post‐transplant management. These consensus guidelines are based on a thorough literature review and discussions among leading dermatologists and haematologists. These recommendations aim to harmonize clinical practice towards improving patient outcomes in these rare but aggressive lymphomas. It is of critical importance to consider allo‐HCT early in the management of eligible patients with high‐risk disease. Advanced stage, large‐cell transformation, relapsed or refractory disease following systemic treatment, and N3‐stage lymph node involvement are indicators that should trigger consultation with a transplant haematologist in parallel with a donor search. Early interaction between dermatologists and transplant haematologists is vital to avoiding delays, which can significantly impact post‐transplant outcomes and survival.</jats:p>

publication_history

received

accepted

published

Allogeneic hematopoietic cell transplantation in patients with advanced mycosis fungoides and Sézary syndrome: a retrospective analysis including 63 consecutive patients with long‐term median follow‐up

Bone Marrow Transplant

This manuscript provides expert recommendations on the role of allogeneic haematopoietic cell transplantation (allo-HCT) for cutaneous T-cell lymphoma (CTCL), specifically mycosis fungoides (MF) and Sezary syndrome (SS). Critical aspects such as patient selection, timing, and bridging therapy are addressed, as well as donor source, conditioning regimens and post-transplant management. These consensus guidelines are based on a thorough literature review and discussions among leading dermatologists and haematologists. These recommendations aim to harmonize clinical practice towards improving patient outcomes in these rare but aggressive lymphomas. It is of critical importance to consider allo-HCT early in the management of eligible patients with high-risk disease. Advanced stage, large-cell transformation, relapsed or refractory disease following systemic treatment, and N3-stage lymph node involvement are indicators that should trigger consultation with a transplant haematologist in parallel with a donor search. Early interaction between dermatologists and transplant haematologists is vital to avoiding delays, which can significantly impact post-transplant outcomes and survival.

Allogeneic haematopoietic cell transplant in cutaneous T‐cell lymphomas: Recommendations from the <scp>EBMT PH</scp>&G Committee

Clinical Summary

What was studied

Key findings

Study limitations

Clinical implications

Related Questions